Business, energy, technology, markets and global industry news from Business News Today

Rein Therapeutics

PharmaDeviceNews Rein Therapeutics
Rein Therapeutics’ FDA Fast Track designation gives LTI-03 closer regulatory engagement as the 120-patient RENEW trial tests whether inhaled therapy can convert encouraging biomarker signals into measurable preservation of lung function. Representative image.
Pharma & Biotech

Can an inhaled peptide do more than slow lung fibrosis? Rein Therapeutics moves LTI-03 deeper into Phase 2

FDA Fast Track gives Rein Therapeutics closer regulatory access as its 120-patient RENEW trial tests whether inhaled LTI-03 can translate promising biomarker effects into measurable preservation of lung function.

Read More
A representative image illustrating Rein Therapeutics’ LTI-03 idiopathic pulmonary fibrosis program as the FDA grants Fast Track designation and the inhaled therapy advances toward closely watched Phase 2 RENEW data in the second half of 2026.
Pharma & Biotech

LTI-03 gets FDA Fast Track status as Rein heads toward Phase 2 IPF data

FDA grants LTI-03 Fast Track status as Rein advances its 120-patient Phase 2 IPF trial toward a closely watched second-half 2026 readout.

Read More